Dare Bioscience, Inc. 8-K

What Happened Daré Bioscience, Inc. filed an 8-K (Item 3.02) disclosing that on March 6, 2026 it completed the second closing of its Regulation A offering. The company issued 17,500 Investor Units at $5.00 per unit. Each Investor Unit consists of one share of Series A Convertible Preferred Stock and two warrants to purchase one share of common stock each.

Key Details

• Offering: Regulation A offering pursuant to Form 1-A (File No. 024-12688), qualified by the SEC on January 5, 2026; offering circular dated January 6, 2026.
• Units issued at second closing: 17,500 Investor Units for aggregate proceeds of $87,500 (17,500 units × $5.00).
• Securities issued: 17,500 shares of Series A Convertible Preferred Stock and Investor Warrants to purchase up to 35,000 shares of common stock (two warrants per unit).
• Offering authorizations: offering was for up to 4,854,000 Investor Units in total.

Why It Matters This filing notifies investors of a completed capital raise under Daré’s previously qualified Reg A offering and the issuance of convertible preferred shares plus warrants. The new securities may result in future increases in common shares outstanding if the preferred stock converts or the warrants are exercised, which is a dilution factor shareholders should monitor. The filing is an unregistered sale under Item 3.02, completed under the terms of the company’s Form 1-A registration statement.